Feb 18 (Reuters) - Swiss generic drug manufacturer Sandoz has agreed to pay $275 million to resolve claims by U.S. consumers and others who accused the company of conspiring with industry rivals ...

The US shift toward steep tariffs will likely make drugs more expensive and limit access for patients, according to one of ...

Looking ahead to 2025, Sandoz said it expects net sales to grow by a mid-single digit percentage in constant currencies.

Four companies have applied to Health Canada to sell copies of Ozempic after its market exclusivity expires on Jan. 4, 2026 ...

Novo Nordisk plans to offer its Wegovy weight loss drug at a reduced cost of $499 per month for cash-paying customers in the ...

Your doctor may have prescribed it for another reason. Cyclosporin Sandoz is only available with a doctor's prescription. It is not addictive. Do not take Cyclosporin Sandoz if you have ever had ...

Based on RBA exchange rate of 1 USD = 1.61 AUD as at 28 th February 2025. [2] Fresh Leaf Analytics, Australian Medicinal Cannabis Market, H1 2021.

A cost-saving effort by NHS England to transition multiple sclerosis (MS) patients from Biogen Inc’s (NASDAQ:BIIB) Tysabri (natalizumab) to the biosimilar drug Tyruko has led to significant side ...

Like rivals Teva Pharmaceutical Industries Ltd. and Viatris Inc., Sandoz copies branded drugs once they lose patent protection, which leads to reduced costs. It manufactures those products largely ...

Sandoz reported a 9% growth in net sales of generics and biosimilars to third parties for 2024, marking a strong first financial year as an independent company. After completing its spin-off from ...